Bioxcel therapeutics reports first quarter 2022 financial results and recent operational highlights

Received fda approval of igalmi™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder in adults

BTAI Ratings Summary

BTAI Quant Ranking